Dr. Kleitos Sokratous is a Scientist at OMass Therapeutics, Oxford, UK. He obtained his BSc in Chemistry from the University of Athens in 2005 and his MSc in Analytical and Pharmaceutical Science from Loughborough University, UK, in 2007. In 2013, he completed his PhD in Chemistry, with focus on biomolecular mass spectrometry, at the University of Nottingham under the supervision of Prof. Neil Oldham. His research was focused on the investigation and quantification of the nature of weak non-covalent biological complexes by electrospray ionization mass spectrometry (ESI-MS). He has also developed and employed ion mobility–mass spectrometry (IM–MS) approaches and molecular dynamic simulations to investigate the effects of cation adducts upon the gas-phase conformational changes of small proteins. In 2013, he moved to Cyprus at the “The Cyprus Institute of Neurology and Genetics”, where he took a leading role in the establishment of the first Biomolecular Mass Spectrometry and MS-based proteomics core facility. During this period, he was involved in multiple projects, which include proteomic analyses, analysis of oligonucleotides, targeted metabolomics and proteomics as well as characterization of biomolecular assemblies and the effects of mutations upon protein conformation. In 2019, he moved to OMass Therapeutics, Oxford, UK, an Oxford University spin-out company applying mass spectrometry technology to drug discovery. His current research focuses on the development and automation of native mass spectrometry platforms for hit-finding activities